Palisade Bio (PALI) Earnings Date & Reports

Key Takeaways

• Palisade Bio (PALI), a clinical-stage biopharmaceutical company, is expected to report its third-quarter 2026 results in mid-November 2026.
• Wall Street's consensus loss estimate for the quarter stands at approximately $0.05 per share, reflecting the company's pre-revenue, development-stage profile.
• As a clinical-stage developer, Palisade Bio generates minimal recurring revenue, so investors will focus on operating expenses, cash runway, and pipeline milestones rather than top-line growth.
• The company ended the second quarter of 2026 with roughly $125.2 million in cash and cash equivalents, which management believes is sufficient to fund operations through key Phase 2 clinical readouts.
• Near-term catalysts tied to lead candidate PALI-2108, including Phase 2 trial enrollment in ulcerative colitis (UC) and a planned investigational new drug (IND) filing for Crohn's disease (CD), will shape the narrative around the report.
• For more on Palisade Bio's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated PALI pages for deeper analysis.
• Discover additional market opportunities by exploring Trending AI Robots to see how automated strategies are scanning the market.

Earnings Context and Why It Matters

Palisade Bio is developing PALI-2108, an oral prodrug designed to deliver targeted, local anti-inflammatory activity for patients with inflammatory bowel disease (IBD) — a group of chronic conditions that includes ulcerative colitis and Crohn's disease. Because the company has no approved products and limited revenue, its quarterly earnings serve less as a profitability gauge and more as a checkpoint on spending discipline, cash runway, and clinical execution. With Phase 2 programs now advancing, this report matters to investors as a progress update on the company's transition from early-stage data toward registration-focused trials. In a biotech environment where funding and pipeline news dominate sentiment, the combination of financial positioning and upcoming trial milestones gives this earnings cycle outsized importance for PALI shareholders.

Earnings Expectations

Analysts tracked by MarketBeat model a consensus loss of approximately $0.05 per share for the third quarter of 2026, based on a small number of estimates. Given Palisade Bio's clinical-stage status, there is little meaningful revenue to forecast; the company reported $0.5 million in one-time license revenue in the prior quarter tied to a milestone under its co-development and distribution agreement with Newsoara. For context, the company posted a loss of $0.05 per share in the first quarter of 2026 and $0.38 per share in the year-ago third quarter. Rather than the headline per-share figure, investors will likely scrutinize research and development (R&D) and general and administrative (G&A) expense trends, as well as any commentary on the pace of enrollment for the Phase 2 ASCENTRA-UC study.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage names like Palisade Bio, it offers a structured way to compare the biotech landscape and identify momentum or pattern-based setups alongside fundamental research.

Market Reaction and Investor Sentiment

Heading into the third-quarter report, sentiment around PALI remains closely tied to the pipeline rather than the income statement. The stock has historically responded more to clinical milestones, financing developments, and analyst coverage than to modest quarter-to-quarter EPS variation. Key risk factors investors are weighing include the pace of spending as the company scales toward Phase 2 trials, the potential for future dilution if additional capital is needed beyond the current cash runway, and the inherent binary risk of early-to-mid-stage clinical development. A clean financial update paired with confirmation that ASCENTRA-UC enrollment and the Crohn's disease IND submission remain on track would likely be viewed constructively, while any signal of timeline slippage or accelerated cash burn could pressure the shares.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, the central story for Palisade Bio is the advancement of PALI-2108 into Phase 2 development. Management has indicated that first-patient enrollment in the Phase 2 ASCENTRA-UC trial for ulcerative colitis is expected in the second half of 2026, with primary efficacy results targeted for the second half of 2027.

A separate near-term catalyst is the planned submission of an investigational new drug (IND) application for the Phase 2 ASCENTRA-CD trial in Crohn's disease, expected in the second half of 2026, with trial commencement targeted for the first quarter of 2027.

Investors will also want to monitor operating expense discipline. With R&D and G&A costs rising to support expanded clinical operations, chemistry, manufacturing and controls (CMC) activities, and translational science, the trajectory of quarterly cash burn will be a key indicator of how far the existing $125.2 million cash balance can stretch.

Finally, watch for any updates on the timeline and design of the Phase 2 programs, as well as broader financing signals. As with most clinical-stage biotechs, the balance between capital efficiency and execution speed will remain a defining theme for PALI through the next several quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations